connected inhaler

By Dave Muoio February 13, 2018
Bensheim, Germany-based drug delivery system manufacturer Sanner GmbH and London, UK-based Amiko — a startup that has leveraged smart sensors and artificial intelligence to develop its connected inhaler and app suite Respiro — are looking to integrate novel technologies into medication packaging to better address the challenges of medication adherence. Following an unspecified investment in the...
By Jonah Comstock January 24, 2018
New Zealand-based smart inhaler company Adherium, which up until now has distributed its products via pharma sales channels in Europe and Australia, plans to expand into the United States in the first half of 2018 with a direct-to-consumer (and direct-to-payer) strategy. “We’ve had a great relationship over the last couple of years with AstraZeneca, we’ve launched in a couple dozen countries now...
By Jonah Comstock January 10, 2018
London-based Amiko Digital Health, which makes connected inhaler and app suite Respiro, has raised a new round of funding. The amount was not disclosed. Sanner Ventures and Breed Reply (a previous investor) led the round. Amiko Digital Health’s flagship product, Respiro, consists of two parts. The first part is a connected inhaler for respiratory disease patients, which measures compliance, lung...
By Heather Mack December 12, 2016
Melbourne, Australia-based smart inhaler company Adherium has been selected to supply the technology for a multi-country research program in Europe that will seek to establish whether home monitoring and mobile health tools can be used to manage asthma. Adherium’s Smartinhaler technology, which uses sensors to track when medication is taken and then sends the data via Bluetooth to mobile devices...
By Heather Mack November 7, 2016
Madison, Wisconsin-based Propeller Health, maker of several smart inhaler sensors and companion apps, has received FDA 510(k) clearance for its latest offering – a sensor that works with GlaxoSmithKline’s Ellipta inhaler. This marks the company’s eighth FDA clearance, and was born out of a partnership the company struck up with GSK last December. Given Propeller's growing familiarity with the...
By Heather Mack October 19, 2016
Madison, Wisconsin-based Propeller Health has closed a $21.5 million Series C financing round, with new investors 3M Ventures, S.R. One, Limited and Hikma Ventures, plus existing investors Safeguard Scientifics and Social Capital. The funding will be used to further Propeller’s digitally-guided therapy platform. Propeller’s aim is to simplify management of chronic respiratory diseases like asthma...
By Jonah Comstock August 22, 2016
Asthma UK, a British nonprofit dedicated to fighting asthma, has released a report highlighting the role connected health has to play in treating asthma and reducing the number of preventable deaths from the disease.  "At Asthma UK we are determined to stop asthma attacks." Asthma UK CEO Kay Boycott writes in the introduction to the report. "Outcomes have plateaued in recent years and this must...
By Jonah Comstock July 27, 2016
The market for digital dose inhalers for asthma and COPD will be worth $3.56 billion in 2024, according to a new prediction from Grand View Research.  Though connected inhalers are a new market, they've seen rapid growth in the last few years with interest from big pharma companies like AstraZeneca and Novartis, major device companies like Philips Respironics, as well as the newer, smaller...
By Jonah Comstock July 20, 2016
Adherium, a Melbourne, Australia-based connected inhaler company, has raised $5.9 million ($8 million Australian) through a private placement of shares with Fidelity. Adherium is publicly traded in Australia. Under the deal, Fidelity will purchase 16 million shares at $0.50 Australian per share, bringing the global asset manager's share in the company to 10 percent. “Fidelity International are...
By Jonah Comstock May 24, 2016
Propeller Health has announced yet another collaboration with a pharmaceutical company. The Madison, Wisconsin-based company will parter with the Chippenham, UK-based Vectura Group, an independent pharma company focused exclusively on inhaler drugs for respiratory conditions. “Digital health has the potential to make respiratory therapies more personal, powerful and convenient for every patient...